Evidence map›Paper›PMID 35304047›Full record

ReviewTrends in biochemical sciences2022

Integrating adipocyte insulin signaling and metabolism in the multi-omics era.

C Martinez Calejman, W G Doxsey, D J Fazakerley, D A Guertin

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in biochemical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 3 countries.

C Martinez CalejmanProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA; Facultad de Medicina, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Centro de Estudios Farmacológicos y Botánicos (CEFYBO), Laboratorio de Endocrinología Molecular (LEM), Universidad de Buenos Aires, Buenos Aires, Argentina.
W G DoxseyProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA.
D J FazakerleyUniversity of Cambridge Metabolic Research Laboratories, Wellcome-Medical Research Council Institute of Metabolic Science, Cambridge CB2 0QQ, UK.
D A GuertinProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA; Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA. Electronic address: David.Guertin@umassmed.edu.
University of Massachusetts Chan Medical School · USConsejo Nacional de Investigaciones Científicas y Técnicas · ARUniversity of Cambridge · GB

Funding

Mechanistic Target of Rapamycin Pathways in Metabolism and Energy ExpenditureR01DK094004 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI GUERTIN, DAVID A · 2013 to 2023
$4.5M
Quantitative and functional analysis of brown fat nutrient fluxes in vivo and its role in organ metabolite exchangeR01DK127175 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI GUERTIN, DAVID A · 2021 to 2025
$2.7M
Acetyl-CoA metabolism and nutrient sensing in adipocytesR01DK116005 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI GUERTIN, DAVID A, WELLEN, KATHRYN ELAINE · 2019 to 2022
$2.0M
Elucidating the AKT-dependent and AKT-independent mechanisms of metabolic control by mTORC2R01CA196986 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI GUERTIN, DAVID A · 2015 to 2019
$1.9M
Medical Research Council MR/S007091/1NCI NIH HHS R01 CA196986NIDDK NIH HHS R01 DK094004NIDDK NIH HHS R01 DK116005NIDDK NIH HHS R01 DK127175
6 · The paper itself

Abstract

Insulin stimulates glucose uptake into adipocytes via mTORC2/AKT signaling and GLUT4 translocation and directs glucose carbons into glycolysis, glycerol for TAG synthesis, and de novo lipogenesis. Adipocyte insulin resistance is an early indicator of type 2 diabetes in obesity, a worldwide health crisis. Thus, understanding the interplay between insulin signaling and central carbon metabolism pathways that maintains adipocyte function, blood glucose levels, and metabolic homeostasis is critical. While classically viewed through the lens of individual enzyme-substrate interactions, advances in mass spectrometry are beginning to illuminate adipocyte signaling and metabolic networks on an unprecedented scale, yet this is just the tip of the iceberg. Here, we review how 'omics approaches help to elucidate adipocyte insulin action in cellular time and space.

Indexed as

Diabetes Mellitus, Type 2InsulinAdipocytesGlucoseHumansSignal TransductionGlucoseInsulinglucoseinsulinmetabolismmetabolomicsphosphoproteomicswhite and brown adipose tissue

Identifiers

PMID35304047
PMCPMC9109456
OpenAlexW4221054399

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.